You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Menopausal Hormone Therapy: For Whom, How, and Why?

  • Authors: Tobie de Villiers, MBChB, MMed (O&G), FRCOG (UK), FCOG (SA); Tommaso Simoncini, MD, PhD; Susan Davis, AO, MBBS, FRACP, PhD, FAHMS; Yu Qi, MD; Antonina Smetnik, MD, PhD
  • CPD Released: 2/24/2022
  • Valid for credit through: 2/24/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US obstetricians and gynecologists practicing in China, Russia, Brazil, India, and more broadly across the Asia-Pacific, Latin America, and Middle East and North Africa regions.

The goal of this activity is to increase knowledge regarding the safety and benefits of menopausal hormone therapy (MHT), and confidence in implementing these therapies in practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest safety data evaluating MHTs
    • Long-term benefits of MHTs
  • Have greater competence related to
    • Individualizing the management of menopause for patients using MHTs


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Tobie de Villiers, MBChB, MMed (O&G), FRCOG (UK), FCOG (SA)

    Consultant Gynecologist
    Mediclinic Panorama and Department of Obstetrics and Gynecology
    Stellenbosch University
    Cape Town, South Africa

    Disclosures

    Disclosure: Tobie de Villiers, MBChB, MMed (O&G), FRCOG (UK), FCOG (SA), has the following relevant financial relationships:
    Advisor or consultant for: CIPLA MEDPRO; Pfizer
    Speaker or a member of a speakers bureau for: Abbott

  • Tommaso Simoncini, MD, PhD

    Professor of Obstetrics and Gynecology
    Chair, Division of Obstetrics and Gynecology
    Department of Clinical and Experimental Medicine
    University of Pisa
    Pisa, Italy

    Disclosures

    Disclosure: Tommaso Simoncini, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Actavis; Astellas; Estetra; Gedeon Richter; Mitsubishi Tanabe; Sojournix
    Speaker or a member of a speakers bureau for: Intuitive Surgical; Shionogi

  • Susan Davis, AO, MBBS, FRACP, PhD, FAHMS

    Professor of Women's Health and NHMRC Senior Principal Research Fellow
    Director, Women's Health Research Program
    Department of Epidemiology and Preventive Medicine
    School of Public Health and Preventive Medicine
    Monash University
    Melbourne, Australia

    Disclosures

    Disclosure: Susan Davis, AO, MBBS, FRACP, PhD, FAHMS, has the following relevant financial relationships:
    Advisor or consultant for: Abbott; Mayne Pharma; Que Oncology; Roche; Southern Star Research; Theramex
    Speaker or a member of a speakers bureau for: Abbott; Besins Healthcare; BioFemme; Biosyent; Mayne Pharma
    Grants for clinical research from: Ovoca BIO; Que Oncology

  • Yu Qi, MD

    Professor of Gynecological Endocrinology and Reproductive Medicine
    Peking Union Medical College Hospital
    Beijing, China

    Disclosures

    Disclosure: Yu Qi, MD, has the following relevant financial relationships:
    Grants for clinical research from: Abbott; Astellas

  • Antonina Smetnik, MD, PhD

    Head, Department of Gynecological Endocrinology
    National Medical Research Centre for Obstetrics, Gynecology and Perinatology
    Ministry of Healthcare of the Russian Federation
    Moscow, Russia

    Disclosures

    Disclosure: Antonina Smetnik, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Acino
    Speaker or a member of a speakers bureau for: Abbott; Acino; Bayer; Besins; Bionorica; Vichy

Editors

  • Katherine Carpenter, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Katherine Carpenter, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Eisai, GW Pharmaceuticals

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Eloise Ballard, PhD, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Susan L. Smith, MN, PhD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Menopausal Hormone Therapy: For Whom, How, and Why?

Authors: Tobie de Villiers, MBChB, MMed (O&G), FRCOG (UK), FCOG (SA); Tommaso Simoncini, MD, PhD; Susan Davis, AO, MBBS, FRACP, PhD, FAHMS; Yu Qi, MD; Antonina Smetnik, MD, PhDFaculty and Disclosures

CPD Released: 2/24/2022

Valid for credit through: 2/24/2023

processing....